Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can
lead to a higher chance of developing heart attacks or strokes. New medications for T2DM
including dapagliflozin, which is a Sodium-Glucose Cotransporter-2 inhibitor (SGLT2)
inhibitor, may help protect the heart and blood vessels.
The overarching objective of this mechanistic study is to learn how a Sodium-Glucose
Cotransporter-2 (SGT2) inhibitor, dapagliflozin, impacts vascular health in patients with
Type 2 Diabetes Mellitus (T2DM). The investigators will compare the changes in vascular
health to changes in endothelial cell (EC) phenotype including non-coding RNA (ncRNA) to
develop evidence supporting the mechanism of cardiovascular benefit of SGLT2 inhibitors. This
study will provide novel information regarding the mechanism of effects of novel treatments
for endothelial function and vascular health in patients with T2DM to reduce cardiovascular
(CV) risk. The research aims to assess the:
- effects of dapagliflozin on EC phenotype.
- impact of dapagliflozin on vasodilator function and additional measures of vascular
health including arterial stiffness and circulating markers of vascular health.